期刊
ANNALS OF ONCOLOGY
卷 24, 期 5, 页码 1189-1202出版社
ELSEVIER
DOI: 10.1093/annonc/mdt001
关键词
diarrhea; enterocolitis; fever; gastrointestinal; neutropenia
类别
资金
- German Federal Ministry of Research and Education (BMBF) [01KN0706]
- Astellas Pharma
- Bayer
- Basilea
- Genzyme
- Gilead Sciences
- Pfizer
- Merck
- Optimer
- Schering-Plough
- Vicuron
- 3M
- Essex/Schering-Plough
- Gilead
- Janssen-Cilag
- Merck/MSD
- Novartis
- Roche
- Shire
- MSD
Background: Cancer patients frequently suffer from gastrointestinal complications. However, a comprehensive, practical and evidence-based guideline on this issue is not yet available. Patients and methods: An expert group was put together by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) to develop a guideline on gastrointestinal complications in cancer patients. For each subtopic, a literature search was carried out in PubMed, Medline and Cochrane databases and the strength of recommendation and the quality of the published evidence for major therapeutic strategies were categorized using a modification of the 'Infectious Diseases Society of America' criteria. Consensus discussions were held on each of the topics. Results: Recommendations were made with respect to non-infectious and infectious gastrointestinal complications. For all recommendations, the strength of the recommendation and the level of evidence are presented. Conclusion: This guideline is an evidence-based approach to the diagnosis and management of gastrointestinal complications in cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据